Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Mark B. Faries et al.|The Lancet|2024Cited by 729
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational studyAndrew Ip, Stuart L. Goldberg, Donald A. Berry et al.|PLoS ONE|2020Cited by 144
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)Kevin Kalinsky, John M. Kirkwood, Krista M. Rubin et al.|Cancer|2017Cited by 125
Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational StudyAndrew Ip, Stuart L. Goldberg, Donald A. Berry et al.|medRxiv|2020Cited by 69
Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19Donald A. Berry, Stuart L. Goldberg, Andrew Ip et al.|PLoS ONE|2021Cited by 9